13 May 2022 - - US-based cell therapy platform developer Paracrine, Inc has appointed David H. Crean, Ph.D. as an independent director, the company said.

Crean is Founder and Managing Partner of Cardiff Advisory LLC, an investment banking firm focused on providing strategic and financial advisory for M and A, partnering and capital financing transactions within the life sciences and healthcare sectors.

Crean is also a Co-Founder and Managing General Partner of Equitos Venture Partners, a life sciences-focused investment firm with a goal to start deploying capital in 2022.

In addition, David is an investment partner with Suncoast Venture Partners and Mesa Verde Venture Partners, two micro life science seed stage and incubator venture funds.

Dr. Crean currently serves as chairman of the board of directors for Phoenix Molecular Designs, Lead Independent director of Histogen, Inc. (NASDAQ: HSTO) and serves on the board of directors of California Life Sciences (Executive Committee), and BIOCOM (chairman of Capital Development).
David is a contributing writer for PharmaBoardroom.com and Forbes.com.

As a result of his trusted and outstanding advisory work, he has been awarded numerous recognitions including San Diego's 500 Most Influential people in 2019 - 2021, 2020 Top Thought Leaders by Axial, M and A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.

David holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo.

He earned a Bachelor of Science Degree in Biology/ Pre-Med from Canisius College. Additionally, he holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University Graziadio School of Management.

Paracrine is a biotechnology company committed to unlocking the potential of autologous stem cells for patients suffering from serious chronic illnesses by discovering, developing, and delivering innovative and effective human therapeutics.

The company is advancing multiple late-stage clinical trials, initially targeting the USD 21bn advanced wound care market segment.

Paracrine's device-enabled cell therapy platform bears the promise of cost-effectively addressing common underlying pathology of debilitating chronic diseases due to its multi-modal mechanisms of action.